"WINDOW" FOR FDA REFORM DEBATE ON SENATE FLOOR SOUGHT BY MAJORITY LEADER LOTT; LABOR COMMITTEE REPORT ON S 1477 RELEASED WITHOUT BUDGET SCORING
This article was originally published in The Gray Sheet
Senate Majority Leader Trent Lott (R-Miss.) says he is "looking for a window to take up" FDA reform legislation following Congress' Fourth of July recess.
You may also be interested in...
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.
Amid several new and updated draft guidance documents and the potential approach of the first approval, interchangeability continues to be a buzzword in US biosimilars. AbbVie has projected that two Humira (adalimumab) biosimilars will hold the designation when they launch in 2023.